866-997-4948(US-Canada Toll Free)

Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017

Published By :

DelveInsight

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 365 Pages

DelveInsights, Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsights Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Scope
The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report provides the marketed drugs information including its sales, development activities and details of patent expiry
The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
The report also gives the information of dormant pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy
Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Report Introduction
Executive Summary Snapshot
Executive Summary
Introduction
Chimeric antigen receptor (CAR) T-cells
History
CARs and Generations
Advantages of CAR-T cells
Adverse Events with CAR T-cell Therapy
Limitations of Existing Technologies for CAR T-Cells
CAR-T Cell Therapy-Analysis
CAR-T Collaboration Deals
CAR-T Cells Therapy Collaborations and Deal Year
Collaborations & Deal Value Trends
Companies collaborations for future developments
CAR-T Acquisitions Deals
CAR-T Cells Therapy Acquisitions Trends
CAR-T Cells Therapy Acquisitions Offerings by Big Giants
New facilityfor the development of CAR-T cells
JCAR015: Major Set Back for Juno Therapeutics
CAR-T Licensing Opportunities
Pipeline Scenario
Pipeline Products under Development-An Overview
Pipeline Products under Development by Company
CAR T-cells Therapeutic Areas & Companies
CAR-T cells Targeted Antigens
CAR-T Therapies-Clinical trials & Completion Year
CAR T-cell Technologies & Companies Involved
CAR-T Safety Switches & Company involved
Companies with Upcoming CAR-T Therapeutics
Pipeline Profiles
Other Active Companies
Miltenyi Biotec
ZMKS International Cancer Therapies Biotechnologies Co. Ltd.
Upcoming Technologies Better than CARs
Market Drivers
Market Barriers
SWOT Analysis
Report Methodology
Consulting Services

List of Table

Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017

List of Chart

Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *